Research programme: GITR antibodies - Five Prime Therapeutics/Inhibrx

Drug Profile

Research programme: GITR antibodies - Five Prime Therapeutics/Inhibrx

Alternative Names: FPA-154; INBRX-110

Latest Information Update: 17 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Inhibrx
  • Class Antibodies
  • Mechanism of Action Immunostimulants; TNFRSF18 protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 04 May 2017 Five Prime Therapeutics plans to file an IND application for FPA 154
  • 11 Nov 2016 Pharmacodynamics data from preclinical studies in Cancer released by Five Prime Therapeutics
  • 15 Jul 2015 Preclinical trials in Cancer in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top